Submitted:
16 April 2023
Posted:
18 April 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
3. Discussion
3.1. Single antibiotic prescription
3.2. Prescription of two antibiotics
3.3. Prescription of three antibiotics
3.4. Prescription to four antibiotics
3.5. Summary study of 301 medical prescriptions
4. Materials and Methods
4.1. Study environment
4.2. Administrative documents
4.3. Methods used
4.4. Data collection and analysis
5. Conclusions
References
- OMS. 2016. Plan d’action mondial pour combattre la résistance aux antimicrobiens.
- OMS.2013. Guide pour établir la surveillance en laboratoire de la résistance aux antimicrobiens.
- Akinde OS, Taiwo MO. Emerging antibiotic resistance in Africa, threat to healthcare delivery. MOJ Biol Med. 2017, 1, 114–115. [CrossRef]
- Haut conseil de la Santé Publique. 2008. Recommandations relatives aux mesures pour prévenir l’émergence des entérobactéries BLSE et lutter contre dissémination.
- Chouchani C, Marra chi R, El Salabi A. Evolution of beta-lactams resistance in Gram –negative bacteria in Tunisia. Crit Rev Microbiol. 2011, 37, 167–177.
- Ghenghesh KS, Rahouma A, Tawil K, Zorgani A, Franca E. Antimicrobial resitance in Libya: 1970-2011. Libyan J Med. 2013, 8, 1–8.
- Kamala Thriemer, Yves Katuala, Bibi Batoko, Jean-Pierre Alworonga, Hugo Devlieger, Christel Van Geet, Dauly Ngbonda, Jan Jacobs. Antibiotic Prescribing in DR Congo: A Knowledge, Attitude and Practice Survey among Medical Doctors and Students. PLoS ONE 2013, 8, e55495. [CrossRef]
- Phoba MF, Lunguya O, Mayimon DV, Lewo di Mputu P, Bertrand S, Vanhoof R, Verhaegen J, Van Geet C, Muyembe JJ, Jacobs J. Multidrug-resistant Salmonella enterica, Democratic Republic of the Congo. Emerg Infect Dis. 2012, 18, 1692–1694.
- De Boeck H, Lunguya O, Muyembe JJ, Glupczynski Y, Jacobs J. Presence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in waste waters, Kinshasa, the Democratic Republic of the Congo. Eur J Clin Microbiol Infect Dis. 2012, 31, 3085–3088. [CrossRef]
- Liesse Iyamba JM, Wambale JM, Takaisi-Kikuni NZ. 2014. Antimicrobial susceptibility patterns of enterobacteriaceae isolated from HIV-infected patients in Kinshasa.Pan Afr Med J. 2014, 17, 179.
- Liesse Iyamba JM, Wambale JM, Lukukula CM, za Balega Takaisi-Kikuni N. High prevalence of methicillin resistant staphylococci strains isolated from surgical site infections in Kinshasa. Pan Afr Med J. 2014, 18, 322. [CrossRef]
- Ministère de la Santé Public RDC.2016. Plan National de Développement Sanitaire 2016-2020.
- OMS, FAO, OIE. 2016. Antimicrobial Resistance: a manual for developing national action plans.
- World Health Organization (WHO). The world medicine situation. Geneva: WHO press. World Health Organization; 2004.
- World Health Organization (WHO). Perspectives politiques de l’OMS sur les médicaments. World Health Organization; 2002.
- J. Mbuyi, H. J. Mbuyi, H. Ngalula, J. Okond’ahoka. A propos de l’observance des règles de prescriptions médicales à Kinshasa. Revue du C.R.I.D.U.P.N. Numéro 071C Avril-Juin 2017, 315-326.
- Muya B. Évaluation de la qualité de la prescription médicale dans la ville de Mbuji-Mayi/ Kasaï-Oriental en République Démocratique du Congo. Revue médicale des grands lacs 2015, 361-368.
- et al. Evaluation of prescriptions for inpatient treatment of malaria and gastroenteritis: Bondeko and St Joseph hospitals in Kinshasa. Santé. 2005, 15, 119–124. [Google Scholar]
- Kalonji Katengele, Fumwakwau Kiniati, Nkanga Isalomboto, Didi Kialengila Mana. The Potential Impact of Self-medication and Drug Misuse Practice Among Youth Population in Kinshasa, Democratic Republic of Congo. [CrossRef]
- In the face of slow progess who offers a new tool and sets a target to accelerate action against antimicribial. https://www.WHO.int/fr/news/item/18-06-2019.
- Nam Vinh Nguyen, Nga Thi Thuy Do, Chuc Thi Kim Nguyen et al. Community-level consumption of antibiotics according to the AWaRe (Access, Watch, Reserve) classification in rural Vietnam. Journal of Antimicrobial Resistance 2021, 10, 1098. [CrossRef]
- Zhussupova, G.; Utepova, D.; Orazova, G.; Zhaldybayeva, S.; Skvirskaya, G.; Tossekbayev, K. Evaluation of Antibiotic Use in Kazakhstan for the Period 2017–2019 Based on WHO Access,Watch and Reserve Classification (AWaRe 2019). Antibiotics 2021, 10, 58. [Google Scholar] [CrossRef] [PubMed]
- Islam, M.A.; Akhtar, Z.; Hassan, M.Z.; Chowdhury, S.; Rashid, M.M.; Aleem, M.A.; Ghosh, P.K.; Mah-E-Muneer, S.; Parveen, S.; Ahmmed, M.K.; et al. Pattern of Antibiotic Dispensing at Pharmacies According to the WHO Access, Watch, Reserve (AWaRe) Classification in Bangladesh. Antibiotics 2022, 11, 247. [Google Scholar] [CrossRef] [PubMed]
- Ines Pauwels, Ann Versporten, Nico Drapier, Erika Vlieghe and Herman Goossens. Hospital antibiotic prescribing in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe) : results from a worldwide point prevalence survey in 69 countries. Journal of Antimicrobial Chemother 2021, 76, 1614–1624.
- Yingfen Hsia, Brian R Lee, Ann Versporten, Yonghong Yang, Julia Bielicki, Charlotte Jackson, Jason Newland, Herman Goossens, Nicola Magrini, Mike Sharland on behalf of the GARPEC and Global-PPS networks. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. www.thelancet.com/lancetgh Vol 7 July 2019.
- World Health Organization (WHO). The world medicine situation. Geneva: WHO press. World Health Organization; 2004.
- WHO Model List of Essential Medicines (20th list). 2017. https://www.who.int/medicines/ news/2017/20th_essential_med-list/en/.
- Kacou-Ndouba, G. Revathi, P. Mwathi, A. Seck, A. Diop, M. J. Kabedi-Bajani, W. Mwiti, M. J. Anguibi-Pokou, I. Morrissey and D. Torumkuney. Results from the Survey of Antibiotic Resistance (SOAR) 2011–14 in the Democratic Republic of Congo, Ivory Coast, Republic of Senegal and Kenya. Journal of Antimicrobial Chemother 2016, 71 Suppl 1, i21-31.
- WHO Access, Watch, Reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, 2021.
- Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014, 69, 881–891. [CrossRef]
- Wilcox MH, Mooney L, Bendall R et al. A case–control study of community-associated Clostridiumdifficile infection. J Antimicrob Chemother 2008, 62, 388–396.
- BergmanM, Huikko S, Huovinen P et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006, 50, 3646–3650. [CrossRef]
- Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004, 48, 2101–2107. [CrossRef]
| N◦ | Antibiotics generic names | n = 164/ (%) | Category (%) |
|---|---|---|---|
| 1 | Amoxicillin | 22 (13,4) |
Access 54 : 32,9 % |
| 2 | Amoxicillin/clavulanic-acid | 20 (12,2) | |
| 3 | Flucloxacillin | 5 (3,0) | |
| 4 | Cefadroxil | 2 (1,2) | |
| 5 | Metronidazole | 2 (1,2) | |
| 6 | Doxycycline | 1 (0,6) | |
| 7 | Penicillin | 1 (0,6) | |
| 8 | Cefalexin | 1 (0,6) | |
| 9 | Ceftriaxone | 51 (31,1) |
Watch 110 : 67,1 % |
| 10 | Azithromycin | 17 (10,4) | |
| 11 | Ciprofloxacin | 12 (7,3) | |
| 12 | Cefixime | 10 (6,1) | |
| 13 | Lincomycin | 6 (3,7) | |
| 14 | Cefotaxime | 4 (2,4) | |
| 15 | Cefpodoxime | 3 (1,8) | |
| 16 | Erythromycin | 3 (1,8) | |
| 17 | Ofloxacin | 2 (1,2) | |
| 18 | Levofloxacin | 1 (0,6) | |
| 19 | Streptomycin | 1 (0,6) | |
| TOTAL | 164 (100) | 164 : 100 % |
| N◦ | Antibiotics generic names | n= 117/(%) | Category (%) |
|---|---|---|---|
| 1 | Amoxicillin + Gentamicin | 6(5,13) | Access 21(18) |
| 2 | Amoxicillin + Furazidin | 1(0,85) | |
| 3 | Amoxicillin + Amikacin | 1(0,85) | |
| 4 | Amoxicillin/clavulanic-acid +Metronidazole | 3(2,56) | |
| 5 | Amoxicillin/clavulanic-acid +Furazidin | 2(1,71) | |
| 6 | Amoxicillin/clavulanic-acid + Ornidazole | 1(0,85) | |
| 7 | Metronidazole + Furazidin | 2(1,71) | |
| 8 | Metronidazole + Doxicycline | 1(0,85) | |
| 9 | Metronidazole + Cefadroxil | 1(0,85) | |
| 10 | Chloramphénicol + Gentamycin | 1(0,85) | |
| 11 | Flucloxacillin + Metronidazole | 1(0,85) | |
| 12 | Penicillin + Doxycycline | 1(0,85) | |
| 13 | Ceftriaxone + Gentamycin | 15(12,82) | Watch 62(53) |
| 14 | Ceftriaxone + Amoxicillin | 11(9,40) | |
| 15 | Ceftriaxone + Metronidazole | 8(6,84) | |
| 16 | Ceftriaxone + Lincomycin | 3(2,56) | |
| 17 | Ceftriaxone + Cefixime | 1(0,85) | |
| 18 | Ceftriaxone + Doxycycline | 1(0,85) | |
| 19 | Ceftriaxone + Ornidazole | 1(0,85) | |
| 20 | Ceftriaxone + Chloramphenicol | 1(0,85) | |
| 21 | Ceftriaxone + Clindamycin | 1(0,85) | |
| 22 | Ceftriaxone + Ciprofloxacin | 1(0,85) | |
| 23 | Lincomycin + Amoxicillin | 2(1,71) | |
| 24 | Lincomycin + Gentamycin | 1(0,85) | |
| 25 | Lincomycin + Kanamycin | 1(0,85) | |
| 26 | Lincomycin + Cefuroxime | 1(0,85) | |
| 27 | Lincomycin + Ofloxacin | 1(0,85) | |
| 28 | Azithromycin + Amoxicillin | 2(1,71) | |
| 29 | Azithromycin + Doxycycline | 2(1,71) | |
| 30 | Ciprofloxacin + Amoxicillin | 1(0,85) | |
| 31 | Ciprofloxacin + Cefadroxil | 1(0,85) | |
| 32 | Ciprofloxacin + Furazidin | 1(0,85) | |
| 33 | Cefotaxime + Chloramphenicol | 1(0,85) | |
| 34 | Cefotaxime + Amoxicillin | 2(1,71) | |
| 35 | Cefixime + Amoxicillin | 1(0,85) | |
| 36 | Kanamycin + Ornidazole | 1(0,85) | |
| 37 | Erythromycin + Penicillin | 1(0,85) | |
| 38 | Norfloxacin/Metronidazole | 8(6,84) | not recommended 34(29) |
| 39 | Ofloxacin/Ornidazole | 8(6,84) | |
| 40 | Ciprofloxacin/Metronidazole | 7(5,98) | |
| 41 | Ceftriaxone/Sulbactam | 6(5,13) | |
| 42 | Ceftriaxone/Tazobactam | 2(1,71) | |
| 43 | Ciprofloxacine/Ornidazole | 2(1,71) | |
| 44 | Cefixime/Ornidazole | 1(0,85) | |
| TOTAL | 117(100) | 117(100) | |
| N◦ | Antibiotics generic names | n=15/(%) | Catégorie (%) |
|---|---|---|---|
| 1 | Penicillin + Chloramphenicol + Doxycycline | 1(6,67) | Access 1(6,6) |
| 2 | Ceftriaxone + Gentamycin +Chloramphenicol | 1(6,67) |
Watch 7(46,7) |
| 3 | Ceftriaxone + Penicillin + Amoxicillin | 1(6,67) | |
| 4 | Ceftriaxone + Gentamycin + Furazidin | 1(6,67) | |
| 5 | Cefotaxime + Metronidazole + Doxycycline | 1(6,67) | |
| 6 | Ceftriaxone + Lincomycin + Gentamycin | 1(6,67) | |
| 7 | Lincomycin + Ceftriaxone + Sulbactam | 1(6,67) | |
| 8 | Cefotaxime + Azythromycin + Oxacillin | 1(6,67) | |
| 9 | Ceftriaxone + Sulbactam + Ornidazole | 1(6,67) |
not recommended 7 (46,7) |
| 10 | Ceftriaxone + Sulbactam + Amoxicillin | 1(6,67) | |
| 11 | Ceftriaxone + Sulbactam + Metronidazole | 1(6,67) | |
| 12 | Ceftriaxone + Sulbactam + Cefixime | 1(6,67) | |
| 13 | Ceftriaxone + Sulbactam + Lévofloxacine | 1(6,67) | |
| 14 | Ciprofloxacin/Metronidazole + Cefotaxime | 1(6,67) | |
| 15 | Ofloxacin/Ornidazole (A) + Azythromycin | 1(6,67) | |
| TOTAL | 15(100) | 15(100) | |
| N◦ | Antibiotics generic names | n= 5/(%) | Category n(%) |
|---|---|---|---|
| 1 | Ceftriaxone/Metronidazole + Ofloxacin + Ornidazole |
1(20) |
not recommended 5(100) |
| 2 | Ceftriaxone/Sulbactam + Norfloxacin + Metronidazole |
1(20) | |
| 3 | Norfloxacin/Metronidazole + Erythromycin + Ornidazole |
1(20) | |
| 4 | Ceftriaxone/Sulbactam + Lincomycin + Metronidazole |
1(20) | |
| 5 | Ceftriaxone/Cefixime + Norfloxacin/Metronidazole |
1(20) | |
| TOTAL | 5(100) | 5(100) | |
| N◦ | Antibiotics generic names | n=463(%) | Category (%) |
|---|---|---|---|
| 1 | Amoxicillin | 51(11,01) |
Access 169(36,5) |
| 2 | Metronidazole | 22(4,75) | |
| 3 | Gentamycin | 26(5,61) | |
| 4 | Amoxicillin/acide clavulanic-acid | 26(5,61) | |
| 5 | Ornidazole | 5(1,08) | |
| 6 | Doxycycline | 8(1,73) | |
| 7 | Furazidin | 7(1,51) | |
| 8 | Flucloxacillin | 6(1,30) | |
| 9 | Chloramphenicol | 5(1,08) | |
| 10 | Penicillin | 5(1,08) | |
| 11 | Cefadroxil | 4(0,86) | |
| 16 | Cefalexime | 1(0,21) | |
| 17 | Clindamycin | 1(0,21) | |
| 18 | Oxacilline | 1(0,21) | |
| 19 | Amikacin | 1(0,21) | |
| 20 | Ceftriaxone | 101(21,38) |
Watch 200(43,20) |
| 21 | Ciprofloxacin | 17(3,67) | |
| 22 | Azithromycin | 23(4,97) | |
| 23 | Lincomycin | 18(3,89) | |
| 24 | Cefixime | 14(3,02) | |
| 25 | Ofloxacin | 3(0,65) | |
| 26 | Cefotaxime | 10(2,15) | |
| 27 | Erythromycin | 5(1,08) | |
| 28 | Cefpodoxime | 3(0,65) | |
| 29 | Kanamycin | 2(0,43) | |
| 30 | Levofloxacin | 2(0,43) | |
| 31 | Cefuroxime | 1(0,21) | |
| 32 | Streptomycin | 1(0,21) | |
| 33 | Ceftriaxone/Sulbactam | 28 (5,61) | 94(20,30) Not recommended |
| 34 | Norfloxacin/Metronidazole | 20(4,32) | |
| 35 | Ofloxacin/Ornidazole | 18(3,89) | |
| 36 | Ciprofloxacin/Metronidazole | 16(3,45) | |
| 37 | Ceftriaxone/Tazobactam | 4(0,86) | |
| 38 | Ciprofloxacin/Ornidazole | 4(0,86) | |
| 39 | Cefixime/Ornidazole | 2(0,43) | |
| 40 | Norfloxacin/Metronidazole | 2(0,43) | |
| TOTAL | 463(100) | ||
| N | WHO ATC group | Aantibiotics classes | n=463(%) | Category (%) |
|---|---|---|---|---|
| 1 | J01CF05 | Penicillins | 63(13,61) |
Access 169(36,5) |
| 2 | J01XD01 | Imidazoles | 27(5,83) | |
| 3 | J01GB03 | Aminoglycosides | 27(5,83) | |
| 4 | J01CR02 | Beta-lactamase inhibitor | 26(5,61) | |
| 5 | J01AA02 | Tetracyclines | 8(1,73) | |
| 6 | J01XE01 | Nitrofuran-derivatives | 7(1,51) | |
| 7 | J01BA01 | Amphenicols | 5(1,08) | |
| 8 | J01DB05 | First-generation cephalosporins | 5(1,08) | |
| 9 | J01FF01 | Lincosamides | 1(0,21)) | |
| 10 | J01DD04 | Third-generation cephalosporins | 128(27,65) |
Watch 200(43,2) |
| 11 | J01FA10 | Macrolides | 28(6,05) | |
| 12 | J01MA12 | Fluoroquinolones | 22(4,75) | |
| 13 | J01FF02 | Lincosamides | 18(3,89) | |
| 14 | A07AA08 | Aminoglycosides | 3(0,65) | |
| 15 | J01DC02 | Second-generation cephalosporins | 1(0,21) | |
| 16 | Third-generation-cephalosporins/ Beta-lactamase-inhibitors | 30(6,48) | Not-recommended 94(20,3) |
|
| 17 | Fluoroquinolones/ Imidazoles | 60(12,96) | ||
| 18 | Third-generation-cephalosporins/Imidazoles | 4(0,86) | ||
| TOTAL | 463(100) | |||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).